About UCSF Search UCSF UCSF Medical Center

Neal L. Benowitz, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
benowitz_neal

Professor, Departments of Medicine, Biopharmaceutical Sciences, Psychiatry, and Clinical Pharmacy, UCSF

nbenowitz@medsfgh.ucsf.edu

Phone: (415) 206-8324 (voice)
Box 1220, UCSF
San Francisco, CA 94143-1222

View on UCSF Profiles


Education

Rennselaer Polytechnic Institute, Troy, NY
University of Rochester School of Medicine, Rochester, NY, MD, 1969, Medicine
Bronx Municipal Hospital Center, Bronx, New York, Intern and Resident, Internal Medicine, 1969-1971
Fellow in Clinical Pharmacology, Department of Medicine, University of California San Francisco, 1971-1972
 


Professional Experience

  • 1973-1972
    Clinical Instructor, Department of Medicine, University of California San Francisco
  • 1975-1972
    Director, Drug Detoxification Unit, San Francisco General Hospital, San Francisco, California
  • 1974-present
    Member of Staff, Medical Service, San Francisco General Hospital, San Francisco, California
  • 1979-present
    Associate Medical Director, San Francisco Bay Area Regional Poison Center, San Francisco, CA
  • 1974-1982
    Asst. Professor, Depts of Medicine and Psychiatry, University of Calif-ornia San Francisco, San Francisco, CA
  • 1981-1982
    Assoc. Professor, Depts of Medicine and Psychiatry, University of California San Francisco, San Francisco, CA
  • 1987-present
    Professor, Departments of Medicine, Psychiatry and Pharmacy, University of California San Francisco, San Francisco, California
  • 1983-present
    Chief, Division Clinical Pharmacology and Experimental Therapeutics, University of California San Francisco
  • 1994-2010
    Vice Chair, Department of Biopharmaceutical Sciences, University of California, San Francisco
  • 2004-present
    Professor of Medicine, Biopharmaceutical Sciences, Psychiatry and Clinical Pharmacy, University of California, San Francisco

Honors & Awards

  • Oscar B. Hunter Award
  • Ove Ferno Award
  • 2002
  • UCSF Annual Distinguished Clinical Research Lecturer
  • Rawls Palmer Award for Progress in Medicine
  • Alton Ochsner Award Relating Smoking and Health
  • 1994-2002
  • NIDA Merit Award
  • American Board of Internal Medicine (Diplomate, 1968)
  • American Board of Medical Toxicology
  • American Board of Clinical Pharmacology
  • American Federation for Clinical Research (President 1996 to 1997)
  • American Society for Clinical Inves-tigation
  • American Society of Clinical Pharma-cology and Therapeutics
  • American Society for Pharmacology and Experimental Therapeutics
  • Association of American Physicians
  • Society for Research on Nicotine and Tobacco (President, 1996-1997)

Selected Publications

  1. Nollen NL, Mayo MS, Ahluwalia JS, Tyndale RF, Benowitz NL, Faseru B, Buchanan TS, Cox LS. Factors associated with discontinuation of bupropion and counseling among african american light smokers in a randomized clinical trial. Ann Behav Med. 2013 Dec; 46(3):336-48.
    View on PubMed
  2. Al-Abri SA, Orengo JP, Hayashi S, Thoren KL, Benowitz NL, Olson KR. Delayed bupropion cardiotoxicity associated with elevated serum concentrations of bupropion but not hydroxybupropion. Clin Toxicol (Phila). 2013 Dec; 51(10):1230-4.
    View on PubMed
  3. Jacob P, Goniewicz ML, Havel CM, Schick SF, Benowitz NL. Nicotelline: a proposed biomarker and environmental tracer for particulate matter derived from tobacco smoke. Chem Res Toxicol. 2013 Nov 18; 26(11):1615-31.
    View on PubMed
  4. Yang J, Pearl M, Jacob P, Delorenze GN, Benowitz NL, Yu L, Havel C, Kharrazi M. Levels of cotinine in dried blood specimens from newborns as a biomarker of maternal smoking close to the time of delivery. Am J Epidemiol. 2013 Dec 1; 178(11):1648-54.
    View on PubMed
  5. David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, Bergen AW, Swan GE, Benowitz NL, Tyndale RF, Conti DV, Brown RA, Lerman C, Niaura R. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction. 2013 Dec; 108(12):2202-11.
    View on PubMed
  6. Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. BMJ. 2013; 347:f5198.
    View on PubMed
  7. Benowitz NL, Goniewicz ML. The regulatory challenge of electronic cigarettes. JAMA. 2013 Aug 21; 310(7):685-6.
    View on PubMed
  8. Dempsey DA, St Helen G, Jacob P, Tyndale RF, Benowitz NL. Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and asian nonsmokers. Clin Pharmacol Ther. 2013 Dec; 94(6):687-94.
    View on PubMed
  9. Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. PLoS One. 2013; 8(8):e70938.
    View on PubMed
  10. Zhu AZ, Renner CC, Hatsukami DK, Benowitz NL, Tyndale RF. CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. Addiction. 2013 Oct; 108(10):1818-28.
    View on PubMed
  11. Dempsey DA, Sambol NC, Jacob P, Hoffmann E, Tyndale RF, Fuentes-Afflick E, Benowitz NL. CYP2A6 genotype but not age determines cotinine half-life in infants and children. Clin Pharmacol Ther. 2013 Sep; 94(3):400-6.
    View on PubMed
  12. St Helen G, Jacob P, Benowitz NL. Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. Nicotine Tob Res. 2013 Nov; 15(11):1939-42.
    View on PubMed
  13. Benowitz NL, Henningfield JE. Reducing the nicotine content to make cigarettes less addictive. Tob Control. 2013 May; 22 Suppl 1:i14-7.
    View on PubMed
  14. Jacob P, Abu Raddaha AH, Dempsey D, Havel C, Peng M, Yu L, Benowitz NL. Comparison of nicotine and carcinogen exposure with water pipe and cigarette smoking. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):765-72.
    View on PubMed
  15. Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics. 2013 Mar; 23(3):135-41.
    View on PubMed
  16. Benowitz NL, Prochaska JJ. Smoking cessation after acute myocardial infarction. J Am Coll Cardiol. 2013 Feb 5; 61(5):533-5.
    View on PubMed
  17. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, Liu J, Lee W, Edlund CK, Hall S, Kwok PY, Benowitz NL, Baker TB, Tyndale RF, Lerman C, Swan GE. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics. 2013 Feb; 23(2):94-103.
    View on PubMed
  18. Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, Benowitz NL, Tyndale RF. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev. 2013 Apr; 22(4):708-18.
    View on PubMed
  19. Jones IA, St Helen G, Meyers MJ, Dempsey DA, Havel C, Jacob P, Northcross A, Hammond SK, Benowitz NL. Biomarkers of secondhand smoke exposure in automobiles. Tob Control. 2014 Jan; 23(1):51-7.
    View on PubMed
  20. Benowitz NL, Dempsey D, Tyndale RF, St Helen G, Jacob P. Dose-independent kinetics with low level exposure to nicotine and cotinine. Br J Clin Pharmacol. 2013 Jan; 75(1):277-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI